Please login to the form below

Not currently logged in
Email:
Password:

adverse events

This page shows the latest adverse events news and features for those working in and with pharma, biotech and healthcare.

Zafgen shares tumble after FDA places hold on diabetes trial

Zafgen shares tumble after FDA places hold on diabetes trial

The company adds that no treatment-related serious adverse events and no cardiovascular safety signals were observed.

Latest news

More from news
Approximately 4 fully matching, plus 291 partially matching documents found.

Latest Intelligence

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    action.”. Adverse events and autoimmunity. Another major challenge for all immunotherapy studies, including combined immunotherapy trials, is the increased potential for autoimmunity. ... The risk of autoimmune responses or toxicities, and indeed all

  • How pharma can unlock the potential of influencer marketing How pharma can unlock the potential of influencer marketing

    Either way, ensure you have a social playbook in place outlining who is responsible for social media monitoring and how you will respond should any adverse events or inappropriate comments occur

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Conventional stem cell transplants cost anywhere between $500, 000 and $1m, while also carrying the risk of having to treat adverse events such as gvhd for example.

  • A new era of smart pharma A new era of smart pharma

    Remote monitoring has its place but sponsors must still be able to collect detailed information on clinical endpoints, serious adverse events (SAEs) and events of special interest. ... SAEs). It is in this area that pharmacovigilance, the science

  • The tipping point The tipping point

    When conditioned to expect a negative response, otherwise known as the ‘nocebo’ effect, patients are more likely to report adverse events, putting a brake on biosimilar adoption.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics